Topical BRAF Inhibitor Relieves Anti-EGFR–Induced Skin Rash

A novel topical formulation of a BRAF inhibitor significantly reduces acneiform rash associated with anti–epidermal growth factor receptor (EGFR) therapies in patients with colorectal cancer, a new study found. This gel could improve treatment adherence, said Anisha B. Patel, MD, lead author of the phase 2 clinical trial…